Simulations Plus sees Q3 revenue $19M-$20M, consensus $22.83M

“Market uncertainties surrounding future funding, drug pricing and potential tariffs are creating significant headwinds for both our pharmaceutical and biotech clients, resulting in budget reductions, project cancellations, and delays that are more pronounced than what we have experienced over the past two years,” said Shawn O’Connor, Chief Executive Officer of Simulations Plus (SLP). “While our software segment has remained relatively resilient, given its role as critical infrastructure in drug development programs, demand for services has proven more sensitive to market volatility and is coming in below our expectations.”